Abstract: The present disclosure is directed to one or more engineered peptide inhibitors against the lactate dehydrogenase A (LDHA) activity in cells. The disclosure also provides compositions, and kits including the one or more peptide inhibitors, and methods of using the one or more peptide inhibitors. The peptide inhibitors and compositions can be used for treatment of conditions in which there is abnormally high LDHA activity, such as cancer or metabolic diseases, infectious diseases, mendelian disorders, inflammatory diseases, neurodegenerative and neuropathological diseases, neuropsychological disorders, obesity and eating disorders, chronic diseases and genetic diseases.

Abstract: A therapeutic lighted catheter that can provide therapeutic light within a biological fluid passage for purposes of treatment and/or curing of materials within the passage. The catheter includes an elongated shaft having a first end and a second end positioned opposite the first end, the elongated shaft including a lumen extending substantially therebetween, and at least one light emitting element positioned within the elongated shaft. A control system is in electronic communication with the light emitting element and provides power thereto such that the powered light emitting element applies a light within the biological fluid passage for therapy and/or curing. The catheter can also include a means to apply a curable material.

Abstract: A suturing device includes a hollow needle. The hollow needle has a length extending between a proximal end and a distal end and defining a lumen having an inner diameter. The suturing device further includes a length of surgical suture having a leading end and a trailing end and an outer diameter smaller than the inner diameter of the lumen. At least a portion of the surgical suture is located within the lumen of the hollow needle. A surgical kit including the suturing device and methods of using the suturing device of the present invention are also disclosed.

Abstract: The present disclosure relates to a method of identifying an agent-of-interest that alters binding or activity of a client protein to a chaperone, co-chaperone, or chaperone-co-chaperone complex, the method including: determining a three-dimensional (3D) structure of a client protein-of-interest; evaluating the 3D structure of the client protein-of-interest to identify an unstable substructure of the 3D structure of the client protein-of-interest; and determining an amino acid sequence of the unstable substructure of the 3D structure of the client protein-of-interest to identify an agent-of-interest that alters binding or activity of a client protein to a chaperone, co-chaperone, or chaperone-co-chaperone complex.

Abstract: The present disclosure is directed to one or more engineered peptide inhibitors against the lactate dehydrogenase A (LDHA) activity in cells. The disclosure also provides compositions, and kits including the one or more peptide inhibitors, and methods of using the one or more peptide inhibitors. The peptide inhibitors and compositions can be used for treatment of conditions in which there is abnormally high LDHA activity, such as cancer or metabolic diseases, infectious diseases, mendelian disorders, inflammatory diseases, neurodegenerative and neuropathological diseases, neuropsychological disorders, obesity and eating disorders, chronic diseases and genetic diseases.

Abstract: The present disclosure relates to methods and compositions comprising dissociated buccal mucosa tissue that are useful for treating a wound. Kits for preparing the liquid suspension of dissociated buccal mucosa tissue and treating the wound are also disclosed.

Abstract: A suturing device includes a hollow needle. The hollow needle has a length extending between a proximal end and a distal end and defining a lumen having an inner diameter. The suturing device further includes a length of surgical suture having a leading end and a trailing end and an outer diameter smaller than the inner diameter of the lumen. At least a portion of the surgical suture is located within the lumen of the hollow needle. A surgical kit including the suturing device and methods of using the suturing device of the present invention are also disclosed.

Abstract: Provided are compositions and methods for inhibiting extracellular matrix metalloproteinase-2 (MMP-2) activity. Inhibition of extracellular MMP-2 activity can be useful for restricting extracellular matrix remodeling, tumor cell migration, cell invasion, and/or metastasis. The compositions comprise mutants of Tissue Inhibitor of Metalloproteinase-2 (TIMP-2), where the tyrosine at position 62, 90 and/or 165 has been substituted with a non-phosphorylatable amino acid or with a phosphomimetic of phosphorylated tyrosine, and/or anti-Src antibodies. The method comprises delivering to an extracellular region of a tissue, a composition comprising a TIMP-2 mutant and/or an anti-Src antibody.

Abstract: The present invention is drawn to methods for detection of the fully human antibodies infiltrated into a solid tissue, and to optimize methods for generating, selecting, and expanding monoclonal antibodies to large numbers for antibody-based therapy and diagnosis. The invention is exemplified in a number of implementations and applications, some of which are summarized below and throughout the specification. In one aspect, the invention is directed to methods for identifying potentially therapeutic fully human antibodies that have infiltrated a solid tissue comprising the following steps: (a) detecting and sorting into one or more subsets a sample of antibodies from an accessible tissue of an individual; (b) characterization of the fully human antibodies; (c) production and purification of the fully human antibody; (d) assessment of the therapeutic and diagnostic activity of fully human antibody.

Abstract: The present invention is drawn to methods for detection of the fully human antibodies infiltrated into a solid tissue, and to optimize methods for generating, selecting, and expanding monoclonal antibodies to large numbers for antibody-based therapy and diagnosis. The invention is exemplified in a number of implementations and applications, some of which are summarized below and throughout the specification. In one aspect, the invention is directed to methods for identifying potentially therapeutic fully human antibodies that have infiltrated a solid tissue comprising the following steps: (a) detecting and sorting into one or more subsets a sample of antibodies from an accessible tissue of an individual; (b) characterization of the fully human antibodies; (c) production and purification of the fully human antibody; (d) assessment of the therapeutic and diagnostic activity of fully human antibody.